Tissue Regenix Share Discussion Threads

[rayrac] 21/12/2015 23:43

Neither is anyone else bam!

But I'm not concerned either, just lost for words that with all the high class backing and ground breaking technology, there's not more interest on this thread...because there isn't!

Amazing!

[bamboo2] 21/12/2015 20:44

SP a bit below my average at the mo. Not concerned.

[rayrac] 21/12/2015 13:10

A little flurry. Could be something in the wind?

[igbertsponk] 18/12/2015 08:52

bamboo - would be much appreciated if you could add in the standard header that is on most threads - the table showing a graph and more importantly the market cap of the company. Ta.

[bamboo2] 17/12/2015 21:42

P r o active also reported this on 16 Dec 2015

Tissue Regenix (LON:TRX) has made it onto Jefferies’ list of top drug industry buys for 2016, with the broker saying it could be a takeover target.

The firm, which has created a porcine tendon for use in anterior cruciate ligament (ACL) and meniscus surgery, has a number of catalysts for shares in the new year, the broker said.

Tissue has also developed a skin graft product using human tissue, as well as heart valves.

The broker said after raising £19mln in February to help develop its meniscus and ligament product - OrthoPure – that it expects the product to be launched by the end of next year.

This has led to a rise in its forecasts for the year, with sales expected to be around £18mln rather than £13mln, while earnings [EBITDA] losses are likely to be reduced to £17mln from previous estimates of £22mln, with the firm swinging to a profit by 2017.

Meanwhile, “the company sees promising data coming through from its cardiac product (heart valve), which is another large attractive market, in our view,” Jefferies said.

It also notes, that with larger firms always on the look-out for new products, “it is not unlikely that Tissue Regenix could become a takeover target.”

“The large medical device companies are grappling with how to move beyond traditional solutions, and TRX is positioned to deliver a neat product that is affordable to bring to market and cost-effective for the payer,” Jefferies said.

[bamboo2] 17/12/2015 21:26

17 Dec 2015 from p r o active

Tissue Regenix (LON:TRX) is a company about to take-off, and chief executive Antony Odell had a clear message for current and potential investors: “watch this space.”

The firm recently began its OrthoPure XT (Porcine tendon) trial treating two patients in Spain with ruptured anterior cruciate ligaments (ACL).

It expects this to be the first step to its rapid commercialisation within the Orthopaedics market, with hope for regulatory sign-off in the form of a CE Mark in the EU by 2017.

Tissue Regenix (TRX) has a good track record of keeping to its targets with its wound care product DermaPure gaining approval from the US government for its state-funded programme Medicare … in just eight months.

“We have had an extremely successful run this year of securing Medicare approval reaching around 65% of Medicare beneficiaries, and we have done some amazing things here with the team in the US,” Odell said.

TRX is a wound care expert, with its Dermapure product being used to rebuild cells in the most difficult of wounds.

Potentially the biggest area of growth for the firm, however, could be its ‘off the shelf’ tendons used in knee repairs.

The trial in Spain saw its OrthoPure XT tendons used in ACL repair – the second most common knee injury surgery in the world.

The company is also in the process of recruiting patients for its OrthoPure XM (Porcine Meniscus) treatment for meniscal tear surgery, also known as a cartilage tear – the most common knee surgery.

By hitting the top two most common knee surgeries, worth around US$4.4bn worldwide, the company is looking to corner this niche market.

The US knee surgery space is worth around US$1.4bn alone, and Odell said: “We have had some initial discussions with the US Food and Drug Administration (FDA) and will continue dialogue with them about the tendon and meniscus products over the next few months.”

Its ground-breaking tendon work, along with the already released wound care product DermaPure, meant broker Jefferies added the firm to its list of drug industry buys for 2016.

The broker reckons OrthoPure XM (Meniscus) will be launched for commercial use in the EU by the end of next year, and recently upped its forecasts based on this, with total company sales expected to be around £18mln for the year.

The reason for the optimism, is that the OrthoPure products are so different from anything else out there on the market.

Put simply, Tissue Regenix takes a tendon or cartliage– either from a human or from a pig – treats it and uses it to replace damaged tissue within the body.

This process, which has had remarkable early results, could revolutionise the market.

“Knee repair technology and procedures really haven’t evolved for the last 30 years so the idea of having an ‘off the shelf’ tendon is actually very attractive to surgeons,” chief executive Odell said.

In the US, there are two options, auto graft, where tendon is taken from another part of the leg, or human donation – tissue donated from someone who has died, he said.

In the EU, there are synthetics available, Odell concedes, but these are so poorly thought of that most surgeons prefer not to use them, and there’s not a lot else in the pipeline for ACL and cartilage tears either.

While 3D printing, a growing phenomenon in the healthcare sector, could one day be able to replace bones, and even parts of organs, tendons are more difficult.

Odell said: “There are a lot of interactions that cannot be replicated by 3D printing so we do not see it as a threat to our business.”

He said that the tendon TRX uses is so close to the original that would be nearly impossible to replicate with 3D printing.

Stem cell research, another down-the-line rival to TRX, also has its issues.

Odell said: “There are still big questions to answer in terms of how you manage live cells which are extremely difficult to handle and transfer that into a hospital.”

This is where Tissue’s tendons come into their own, as they can be handled easily and are convenient to transport and use within a hospital setting.

What’s more, the fact they can be stored at room temperature and have significantly longer shelf lives than other tendons make the product a much better fit for surgeons.

With talks already begun with the FDA, and in Europe, and a superior product to anything currently on the market, it is not surprising that Jefferies is expecting big things from Tissue Regenix in the coming year.

[ali47fish] 14/12/2015 09:59

yet another fall always on no news?

[andrewbaker] 11/12/2015 11:47

Woodford and Invesco have been buying recently, so I'm thinking about taking another nibble myself: the price is definitely attractive if one believes in the company's products, which I do. Plus, health is a growth market, and will continue to be for the foreseeable future, so this is a buy and long term hold, with the added attraction that it may get taken over. Barriers to entry are high as well; so all-in-all, a pretty good investment at these levels, IMHO.

[rayrac] 09/12/2015 18:08

Well, the spring hasn't sprung...looking back to my previous post.

Demand? What demand?

[ali47fish] 07/12/2015 16:29

what's happening next week - is ther an update or what

[luminoso] 07/12/2015 15:38

Ouch, big sells ?

[luminoso] 06/12/2015 12:18

Thanks, bamboo.

[rayrac] 06/12/2015 12:05

Looking forward to next week. Never know, it could really spring to life....did a little bit last week!

[bamboo2] 04/12/2015 17:24

Welcome scottishfield.

luminoso, The co is currently involved [in the USA] in a wide ranging, stage four, clinical trial of the Dermis product [Dermapure]. This is not due to complete for a while, but that has not stopped the co releasing some selected highlights during the CMD's and at other oppertunities.

Whilst it will also be some time before the final conclusions are drawn on both the meniscus and tendon products, I would imagine management will jump at the chance to illustrate their effectiveness. Given that the first meniscus ops were some time ago [Feb/March 2015], I guess outcomes will be known first or second quarter 2016.
e

[luminoso] 04/12/2015 11:32

Great RNS. I guess a successful outcome of the operations is more likely to generate investor interest than the operations themselves. Wonder how long before the outcomes are announced.

[scottishfield] 04/12/2015 11:31

Took a first position here today with a few buys.

[32sam] 04/12/2015 08:24

its on my radar!! Good news, market is huge for such injuries, new being swallowed by energy conferences & OPEC etc. Should pick up as potential is resolved imho.

sam

[rayrac] 04/12/2015 08:07

More good vibes! It's rather obvious that TRX are not on many peoples radar just yet? Otherwise there would be some heavier trading.

[bamboo2] 04/12/2015 08:05

04 December 2015

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

World's first OrthoPure(TM) XT (dCELL(R) Tendon) implants successfully undertaken at Barcelona Hospital

York 4th December 2015, Tissue Regenix Ltd, (AIM:TRX) "Tissue Regenix" or "The Group" the regenerative medical device company, is pleased to announce that two patients have received the first OrthoPure(TM) XT decellularised tendons using Tissue Regenix patented dCELL(R) technology. This has been done as part of a clinical safety study by Tissue Regenix which is being conducted to secure a CE mark to enable launch of the OrthoPure(TM) XT in the EU in 2017.

Orthopaedic & Trauma Surgeon, Dr. Gabriel Oliver performed both surgical procedure at the Bellvitge University Hospital in Barcelona on Thursday 3(rd) December. Both patients had ruptured an ACL due to recreational sports; the first a 31 year old male playing football, the second a 32 year old female injured whilst skiing.

Dr Oliver was able to replace damaged anterior cruciate ligament (ACL) with TR's decellularised tissue which allows the surgeon to make a 'like for like' repair.

The ACL is responsible for 90% of the stability of the knee and instability can lead to long term damage and the need for further high cost procedures.

Tissue Regenix's OrthoPure(TM) XT has been developed as an effective and cost-efficient solution to ACL rupture which is the second most common injury of the knee requiring reconstruction, around 900,000 ACL procedures performed in the US & Europe in 2014.

Peter Hamer, Commercial Director of Orthopaedics at Tissue Regenix commented:

This is an exciting time for Orthopaedics at Tissue Regenix. The beginning of the OrthoPure(TM) XT clinical trial is the next step towards securing regulatory approval to launch in 2017. The main surgical options for this type of injury are currently limited to taking tissue from the patient, human donor material and, to a much lesser extent, using synthetics. An 'off the shelf' biologic replacement would represent a significant step forward in this type of surgery.

Additionally, we hope the recruitment of the first 20 patients in the OrthoPure(TM) XM (meniscus) clinical trial will be completed early Q1 2016 which keeps us on track for CE mark submission H2 2016"

[rayrac] 30/11/2015 11:07

Thanks bamboo. I, like many I assume, only visit here, say once a week! Even though I have a decent interest in the shares...and outcome.🚀

[bamboo2] 25/11/2015 21:16

Ray, Once the meniscus product obtains its CE mark [2016] and becomes available off the shelf, it will make the majority of current tech for meniscus transplant and repairs obsolete. It's a massive market, with extremely limited competition and huge barriers to entry.

Houlihan-Burne has described this as 'the holy grail of orthopedic surgery'.
A xenograft means virtually unlimited supplies for the UK/ROW exc USA. In the US, initially an allograft will be offered.

Patience is definitely the answer.

[luminoso] 25/11/2015 18:26

Well, they shook me to add another 8500 shares. All adds up, when they get bought out in years to come.

[rayrac] 25/11/2015 16:54

Lack of news, so mm's trying to shake us...in or out?

Patience I suppose is the answer.

[ali47fish] 25/11/2015 15:40

further down- ridiculous on no news